gadolinium(3+) ion 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate

• ChemBase ID: 479
• Molecular Formular: C17H29GdN4O7
• Molecular Mass: 558.68476
• Monoisotopic Mass: 559.12772729
• SMILES: [Gd+3].OC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C
• Canonical SMILES: CC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Gd+3]
• InChI: InChI=1S/C17H32N4O7.Gd/c1-14(22)10-18-2-4-19(11-15(23)24)6-8-21(13-17(27)28)9-7-20(5-3-18)12-16(25)26;/h14,22H,2-13H2,1H3,(H,23,24)(H,25,26)(H,27,28);/q;+3/p-3
• InChIKey: DPNNNPAKRZOSMO-UHFFFAOYSA-K

NAMES AND DATABASE IDS

Names

• IUPAC name: gadolinium(3+) ion 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate
• IUPAC Traditional name: gadolinium(3+) 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate
• Brand Name: ProHance; Prohance Multipack
• Synonyms: Gadoteridol

Database IDs

• CAS Number: 120066-54-8
• PubChem SID: 160963942; 46505738
• PubChem CID: 60714

CALCULATED PROPERTIES

JChem

• Acid pKa: 0.7627792
• H Acceptors: 11
• H Donor: 1
• LogD (pH = 5.5): -8.556765
• LogD (pH = 7.4): -10.277726
• Log P: -7.54848
• Molar Refractivity: 133.5526 cm^3
• Polarizability: 39.391407 Å^3
• Polar Surface Area: 153.58 Å^2
• Rotatable Bonds: 8
• Lipinski's Rule of Five: false

ALOGPS 2.1

• Log P: 0.36
• LOG S: -1.77
• Solubility (Water): 1.12e+01 g/l

DETAILS

DrugBank - DB00597

• Drug Groups: approved
• Description: Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
• Indication: Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
• Affected Organisms: Humans and other mammals
• Half Life: Distribution 12 minutes (mean), elimination 100 minutes (mean).
• Elimination: Gadoteridol is eliminated in the urine with 94.4 ± 4.8% (mean ± SD) of the dose excreted within 24 hours post-injection.
• Distribution: * 204 ± 58 mL/kg
• Clearance: * 1.50+/- 0.35 mL/ min/kg; * renal cl=1.41 +/- 0.33 mL/ min/kg